Purpose-built for physicians What to know about using non-insulin agents in type 1 diabetes Susan Weiner, MS, RDN, CDCES, FADCES, talks with Joshua J
The second game-changing article that came out is called SELECT, in which it's the very first study that we could say these drugs are disease-modifying and change lives, save lives
Doctors say there are several reasons why GLP-1 medications may not work for you, but there are alternative options available
This information supports more informed decisions about dosing, concurrent medications, and monitoring frequency tailored to your unique metabolic profile and lipid targets
Buena parte de ese cambio puede atribuirse a la irrupcin de la semaglutida , un medicamento aprobado en 2021 para el tratamiento de la obesidad y que, pese a su alto costo y limitada disponibilidad, ha demostrado ser extraordinariamente eficaz